Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metoprolol + morphine is a combination of two pharmaceutical drugs, each with distinct mechanisms and indications. Metoprolol is a cardioselective beta-blocker that acts primarily as an antagonist at the beta-1 adrenergic receptor in cardiac tissue, reducing heart rate, contractility, and blood pressure. It is indicated for hypertension, angina pectoris, heart failure, myocardial infarction recovery, atrial fibrillation/flutter, and other cardiovascular conditions[2][3][6]. Morphine is an opioid analgesic that acts as an agonist at mu-, kappa-, and delta-opioid receptors in the central nervous system to relieve moderate to severe pain[8]. The combination may be used in clinical settings where both cardiovascular management (metoprolol) and pain control (morphine) are required; however, co-administration can result in additive effects on lowering blood pressure and should be monitored closely due to risk of hypotension or bradycardia[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metoprolol + morphine.